Targeted Agents (cont.)
Chapter 2Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.
Targeted Agents
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Radium-223
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.
Chemotherapy
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the role of cytotoxic chemotherapy in treatment of castration resistant prostate cancer and metastatic castration resistant prostate cancer.
Immunotherapy
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss immunotherapy approaches to treatment of metastatic castration resistant prostate cancer.
Treatment Sequencing
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal sequencing of therapies in metastatic castration resistant prostate cancer.
Androgen Deprivation Therapy
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss androgen deprivation therapy in advanced/metastatic prostate cancer.
Duration of Androgen Deprivation Therapy
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal duration of androgen deprivation in the treatment of high-risk and very high-risk locally advanced prostate cancer.
Docetaxel in Combination with Androgen Deprivation Therapy
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of docetaxel in combination with androgen deprivation therapy in men with prostate cancer.
Androgen Deprivation Therapy Resistance
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss resistance to androgen deprivation therapy in men with prostate cancer.
Androgen Deprivation Therapy and Radiation
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of radiation with androgen deprivation therapy in men with prostate cancer.
Predictions for the Future
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss their predictions for advances in the treatment of men with prostate cancer in next five years.
